# Contents

**List of Contributors** xv
**Preface** xix
**Acknowledgments** xx

**1 Introduction to Cardiovascular Diseases and Herbal Medicine** 1

*Gnaneswari Kodi, Suneetha Achanti, Thirumala Devi Siriki, and Sree Geetha A*

1.1 Introduction, 1
1.1.1 Cardiovascular Diseases, 1
1.1.2 Epidemiology of Cardiovascular Diseases, 1
1.1.3 Risk Factors of Cardiovascular Diseases, 1
1.1.4 Major Types of Cardiovascular Diseases, 2
1.2 Conventional Management of Cardiovascular Diseases, 6
1.2.1 Goals of Management, 6
1.2.2 Major Aspect of Traditional Cardiovascular Disease Management, 6
1.3 Herbal Medicine, 8
1.3.1 Historical Background, 8
1.3.2 Principles of Herbal Medicine, 9
1.3.3 Forms of Herbal Preparations, 9
1.3.4 Role and Safety of Herbal Medicine in Modern World, 9
1.3.5 Advantages, Challenges, and Limitations of Herbal Medicine, 9
1.3.6 Herbal Medicine in Cardiovascular Health, 9
1.4 Conclusion, 13
References, 14

**2 Phytochemical-Based Interventions for Cardiovascular Complications: Mechanistic Insights and Therapeutic Promise** 17

*Lakshmana Rao Atmakuri, Kamal Dua, Ramesh Alluri, and Anupama Baratam*

2.1 Introduction, 17
2.2 Classification, Dietary Sources, and Therapeutic Potential, 17
2.3 Molecular Targets in Cardiovascular Pathology, 19
2.4 Phytochemical Cardioprotection Mechanisms, 19
2.5 Prominent Phytochemicals and Their Therapeutic Profiles, 20
2.6 Strategies to Enhance Phytochemical Delivery, 20
2.7 Preclinical and Clinical Evidence, 20
2.8 Artificial Intelligence in Phytochemical Research, 21
2.9 Regulatory Framework and Standardization, 22
2.10 Innovations in Phytochemical Therapeutics, 23
2.11 Challenges and Future Perspectives, 23

COPYRIGHTED MATERIAL

2.12 Conclusion, 24
References, 24

3 Traditional and Modern Strategies in Cardiovascular Therapy: Innovative Blends 27

*Sathyamoorthy Nandhakumar, Dhanalekshmi Unnikrishnan Meenakshi, Thangavel Mahalingam Vijayakumar, and Pavan Kumar Chintamaneni*

3.1 Introduction, 27
3.2 Global and Regional Burden of CVD, 28
3.3 Etiology of Cardiovascular Diseases, 28
3.3.1 Hypertension, 28
3.3.2 Diabetes Mellitus, 28
3.3.3 Obesity, 28
3.3.4 Smoking, 29
3.4 Pathophysiology of Cardiovascular Diseases, 29
3.4.1 Atherosclerosis, 29
3.4.2 Endothelial Dysfunction, 30
3.4.3 Thrombosis, 30
3.5 Conventional Drug Therapies, 30
3.5.1 Lipid-Lowering Agents, 30
3.5.2 Antihypertensive Drugs, 30
3.5.3 Antithrombotic Therapy, 30
3.6 Traditional Systems of Medicine and Their Concept of Cardiovascular Health, 31
3.7 The Challenges of Traditional Medicine, 33
3.7.1 The Regulatory Hurdles, 33
3.7.2 Bioavailability – A Barrier to Clinical Translation of Herbs, 33
3.8 Blending Nanotechnology and Traditional Medicine for Improved CVD Management, 35
3.8.1 *Camellia sinensis*, 35
3.8.2 *Curcuma longa*, 36
3.8.3 *Allium sativum*, 37
3.8.4 *Salvia miltiorrhiza*, 37
3.8.5 *Withania somnifera*, 37
3.8.6 *Ginkgo biloba*, 38
3.8.7 *Panax ginseng*, 38
3.8.8 *Commiphora wightii*, 38
3.9 Conclusion, 38
References, 39

4 Glycosides, Flavonoids, Polyphenols: Natural Cardioprotective Agents 42

*Bondada N.B. Vaidehi, Rudolf Bauer, Akshintala Sree Gayatri, and Bodapati Raju*

4.1 Introduction, 42
4.2 Glycosides, 42
4.2.1 Classification of Glycosides, 42
4.2.2 Examples of α-Glycosides, 46
4.2.3 Glycosides as Cardioprotective Agents, 47

4.3 Flavonoids, 47
4.3.1 Classification, 47
4.3.2 Causes for Cardiovascular Problems, 49
4.3.3 Mechanisms of Cardioprotective Action, 49
4.3.4 Specific Flavonoids with Cardioprotective Effects, 49
4.4 Polyphenols, 50
4.4.1 Types of Polyphenols, 50
4.4.2 Occurrence and Content, 52
4.4.3 Cardioprotective Effect, 52
4.5 Conclusion, 53
References, 53

**5 Herbal Antihypertensives: Mechanisms and Clinical Evidence 56**

*Garlanka Venkata Naga Kiranmayi, N. Harikrishnan, Long Chiau Ming, and Karumanchi Srikanth*

5.1 Introduction, 56
5.1.1 Global Burden and Clinical Importance of Hypertension, 56
5.1.2 Current Therapeutic Approaches and Their Challenges, 56
5.1.3 Historical and Contemporary Use of Herbal Antihypertensives, 56
5.1.4 Increasing Scientific Validation and Integration into Modern Therapy, 56
5.2 Pathophysiology of Hypertension, 56
5.2.1 Regulation of Blood Pressure: An Integrated Physiological Perspective, 56
5.2.2 Pathogenic Mechanisms Contributing to Hypertension, 57
5.2.3 Renin-Angiotensin-Aldosterone System, 57
5.3 Therapeutic Implications of Hypertension Pathophysiology, 58
5.3.1 Molecular and Cellular Mechanisms in Hypertension, 58
5.3.2 Vascular Remodeling and Arterial Stiffness, 58
5.3.3 Neurohormonal and Renal Contributions, 58
5.3.4 Genetic and Epigenetic Factors, 58
5.4 Common Herbal Antihypertensives, 58
5.4.1 Overview of Herbal Remedies in Hypertension Management, 58
5.4.2 Additional Noteworthy Herbs, 59
5.5 Pharmacological Mechanisms of Herbal Antihypertensives, 60
5.5.1 Enhancement of Endothelial Function and Nitric Oxide Bioavailability, 60
5.5.2 Inhibition of RAAS, 60
5.5.3 Modulation of Sympathetic Nervous System Activity, 60
5.5.4 Calcium Channel Blockade Leading to Vascular Smooth Muscle Relaxation, 60
5.5.5 Diuretic Effects and Regulation of Fluid Balance, 61
5.5.6 Anti-inflammatory and Antioxidant Properties, 61
5.5.7 Modulation of Ion Channels Beyond Calcium, 61
5.5.8 Synergistic and Multi-targeted Actions of Herbal Antihypertensives, 61
5.5.9 Modulation of Vascular Remodeling and Extracellular Matrix, 61
5.5.10 Neuroprotective Effects and Central Blood Pressure Regulation, 61
5.5.11 Safety Assessment, Toxicological Evaluation, and Interactions Between Herbs and Medications, 61
5.5.12 Challenges in Herbal Antihypertensive Research, 62

5.6 Clinical Trials of Herbal Antihypertensives, 62
5.6.1 Comprehensive Overview of Clinical Research on Herbal Antihypertensives, 62
5.6.2 Randomized Controlled Trials: Evidence from High-Quality Studies, 62
5.6.3 Insights from Meta-Analyses and Systematic Reviews, 63
5.6.4 Adjunctive Use of Herbal Agents with Conventional Antihypertensives, 63
5.6.5 Limitations and Future Perspectives in Clinical Research, 63
5.6.6 Safety, Toxicology, and Regulatory Aspects of Herbal Antihypertensives, 63
5.6.7 Future Perspectives and Challenges in Herbal Antihypertensive Research and Application, 64
5.6.8 Detailed Mechanisms of Action of Herbal Antihypertensives, 64
5.6.9 Prominent Herbal Agents with Clinical Evidence in Hypertension Management, 65
5.6.10 Phytochemical Constituents Underlying Antihypertensive Effects, 66
5.6.11 Clinical Evidence and Trial Insights, 66
5.6.12 Integration of Herbal Antihypertensives in Modern Therapeutic Strategies, 66
5.6.13 Pharmacokinetics and Bioavailability of Herbal Antihypertensives, 66
5.6.14 Challenges in Standardization and Quality Control, 67
5.6.15 Emerging Research Trends and Future Directions, 67
5.6.16 Conclusion, 68
References, 68

**6 Natural Lipid-Lowering Agents: Role in Dyslipidemia and Atherosclerosis 71**

*Evelyn Sharon Sukumaran, Garlanka Venkata Naga Kiranmayi, K. Ravi Shankar, and Nakkala Danamurthy*

6.1 Introduction, 71
6.2 Dyslipidemia, 71
6.3 Atherosclerosis, 72
6.4 Pathogenesis of Atherosclerosis, 73
6.5 Natural Lipid-Lowering Agents, 74
6.5.1 Polyphenols, 74
6.5.2 Phytosterols, 75
6.5.3 Omega 3 Fatty Acids, 76
6.5.4 Alkaloids, 77
6.5.5 Probiotics, 78
6.5.6 Dietary Fibers, 79
6.6 Conclusion, 80
References, 80

**7 Herbal Anticoagulants, Antiplatelets, and Thrombolytics for Cardiovascular Health 83**

*Sadhe Amala, Sarikonda Tripura Venkata Raghavamma, and Asapu Hema KIranmayi*

7.1 Introduction, 83
7.2 Hemostasis, 83
7.2.1 Primary Homeostasis, 84
7.2.2 Secondary Hemostasis, 84
7.2.3 Fibrinolysis, 85
7.3 Cardiovascular Protection, 86

7.3.1 Mechanisms of Cardiovascular Protection, 86
7.3.2 Role of Herbal Drugs in Cardioprotection, 87
7.4 Plant Bioactive Compounds, 88
7.4.1 Herbal Anticoagulants, 88
7.4.2 Herbal Antiplatelets, 90
7.4.3 Herbal Thrombolytics, 92
7.5 Conclusion, 93
References, 94

**8 Barriers and Breakthroughs in Herbal Drug Formulation and Delivery Systems 96**

*Thummala Udaya Kumar*

8.1 Introduction, 96
8.2 Barriers in Herbal Drug Formulation and Delivery, 96
8.2.1 Poor Solubility and Dissolution, 97
8.2.2 Instability of Herbal Bioactives, 97
8.2.3 Lack of Standardization and Quality Control, 97
8.2.4 Poor Bioavailability and Rapid Metabolism, 98
8.2.5 Safety and Toxicity Concerns, 98
8.2.6 Regulatory Challenges, 98
8.2.7 Technical and Manufacturing Barriers, 98
8.3 Breakthroughs in Herbal Drug Delivery Systems, 98
8.3.1 Nanotechnology-Based Approaches, 99
8.3.2 Vesicular drug delivery system, 99
8.3.3 Lipid-Based Formulations, 99
8.3.4 Polymeric and Hydrogel Systems, 99
8.4 Advances in Extraction and Processing Techniques, 100
8.5 Artificial Intelligence and Computational Approaches, 100
8.6 Regulatory Framework for Herbal Drug Formulation and Delivery Systems, 100
8.7 Pillars of Herbal Drug Regulation, 101
8.8 Regulatory Approaches to Herbal Medicines, 102
8.9 Innovations in Herbal Drug Regulation, 102
8.10 Breakthrough Concepts in Herbal Regulation, 102
8.11 Future Outlook, 103
8.12 Conclusion, 103
References, 104

**9 Targeted Delivery of Herbal Compounds for Cardiovascular Health Using Liposomes, Phytosomes, and Self Nano-Emulsified Drug Delivery Systems 107**

*Pathuri Raghuveer, Haya Khader Ahmed Yasin, Shakil Akthar, and Grandhi Srikar*

9.1 Introduction, 107
9.1.1 Role of Phytochemicals in Cardiovascular Disease Treatment, 107
9.2 Phytochemicals for Cardiovascular Disease Therapy, 108
9.3 Physicochemical and Pharmacokinetic Challenges, 108

9.3.1 Poor Solubility and Bioavailability, 108
9.3.2 Rapid Metabolism and Systemic Elimination, 108
9.3.3 Instability and Degradation, 109
9.3.4 Clinical Consequences and Formulation Implications, 109
9.4 Nanotechnology-Based Delivery Strategies, 110
9.4.1 Liposomes: Composition, Mechanism, Advantages, and Advances, 110
9.4.2 Phytosomes: Structure, Mechanism, Advantages, and Innovations, 111
9.4.3 Other Nanodelivery Systems: Nanoemulsions, Polymeric Micelles, and Nanoparticles, 112
9.5 Limitations of Nano-Based Delivery Systems, 113
9.5.1 Technical and Practical Limitations, 113
9.5.2 Stability and Scalability Concerns, 114
9.6 Regulatory Challenges, 114
9.6.1 Current Regulatory Framework for Phytochemicals, 114
9.6.2 Challenges Specific to Nano-Based Formulations, 114
9.6.3 Strategies to Overcome Regulatory Barriers, 115
9.7 Future Perspectives and Research Directions, 115
9.7.1 Emerging Innovations in Nano-Formulation Technology, 115
9.7.2 Clinical Trials and Future Developments, 115
9.8 Conclusion, 115
References, 116

**10 Microneedles, Hydrogels, and Transdermal Patches for Cardiovascular Applications 119**

*Raghuveer Pathuri, S. M. Khamanga, M. V. N. L. Chaitanya, and Pavan Kumar Chintamaneni*

10.1 Introduction, 119
10.2 Phytomedicine in CVD Therapy, 119
10.2.1 Key Phytochemicals with Cardioprotective Action, 119
10.2.2 Challenges in the Delivery of Herbal Drugs, 120
10.2.3 Rationale for Transdermal Drug Delivery Approaches, 121
10.3 Fundamentals of Transdermal Drug Delivery Systems, 121
10.3.1 Anatomy and Physiology of Skin in Relation to Drug Transport, 121
10.3.2 Barrier Function of the Stratum Corneum, 122
10.4 Microneedle Systems in Cardiovascular Therapy, 122
10.4.1 Types of Microneedles and Materials Used in Fabrication, 122
10.4.2 Mechanism of Action of Microneedles in the Management of CVDs, 123
10.4.3 Delivery of Synthetic and Phytochemical Molecules by Microneedles, 123
10.4.4 Advantages of Microneedle-Based Delivery, 124
10.4.5 Challenges and Limitations, 124
10.4.6 Future Prospects of Microneedles in CVDs Therapy, 125
10.5 Hydrogels of Cardiovascular Drug Delivery, 125
10.5.1 Structural Composition and Classification of Hydrogels, 125
10.5.2 Drug Encapsulation and Release from Hydrogels, 126
10.5.3 Hydrogel-Based Delivery of Cardiovascular Drugs, 126
10.5.4 Injectable Hydrogels for Myocardial Repair, 127
10.5.5 Advantages of Hydrogel-Based Drug Delivery, 127

10.5.6 Challenges and Limitations, 127
10.5.7 Future Perspectives, 128
10.6 Transdermal Patches in Cardiovascular Applications, 128
10.6.1 Fundamentals of TD Patch Technology, 128
10.6.2 Materials Used in the Fabrication of TD Patches, 129
10.6.3 Fabrication of TD Patches, 129
10.6.4 Delivery of CVD Therapeutics with TD Patches, 129
10.6.5 Advantages in TD Drug Delivery of Herbal Cardiovascular Therapeutics, 130
10.6.6 Challenges and Limitations, 130
10.6.7 Future Prospects of TD Patch-Based Delivery of Herbal Drugs in CVDs, 130
10.7 Comparison of Microneedles, Hydrogels, and TD Patches, 131
10.8 Regulatory Landscape of Herbal Drug-Loaded Microneedles, Hydrogels, and Transdermal Patches, 131
10.9 Emerging Trends and Future Prospects, 132
10.10 Conclusion, 132
References, 132

**11 Preclinical and Clinical Studies on Herbal Cardiovascular Therapies 136**

*Naga Venkata Lakshmi Sirisha Mulukuri, Talluri Sesha Rajeswari, Ponakampalli Rambabu, and Dasari Santhi Krupa*

11.1 Introduction, 136
11.2 Preclinical Studies for Testing of Herbal Medicine in Cardiovascular Disorders, 136
11.3 Scientific Studies on Some Herbs Used in Cardiovascular Disorders, 139
11.3.1 Hawthorn, 139
11.3.2 Garlic, 141
11.3.3 Turmeric, 142
11.3.4 Berberine, 143
11.3.5 Quercetin, 143
11.3.6 Catechins, 144
11.3.7 Silymarin, 146
11.3.8 *Ginkgo biloba,* 147
11.4 Conclusion, 147
References, 147

**12 Toxicological and Pharmacokinetic Considerations in Herbal Medicine 150**

*Madhavi Latha Samala, Anu Pravallika Janipalli, Gowri Gollu, and Nalini Mathala*

12.1 Introduction, 150
12.1.1 Complexity of Herbal Constituents, 150
12.1.2 Need for Integrated Toxicological and Pharmacokinetic Evaluation, 150
12.2 Toxicological Considerations in Herbal Medicine, 151
12.2.1 Types of Toxicity, 151
12.2.2 Contaminants and Adulterants, 152
12.2.3 Herb–Drug Interactions, 152
12.2.4 Allergic and Idiosyncratic Reactions, 153

12.2.5 Individual Susceptibility and Risk Factors, 154
12.2.6 Toxicological Testing Methodologies (*In Vitro, In Vivo, In Silico*), 154
12.3 Pharmacokinetic Considerations of Herbal Medicine, 155
12.3.1 Pharmacokinetics of Herbal Medicines, 155
12.3.2 Flavonoids, 155
12.3.3 Terpenoids, 157
12.3.4 Carotenoids, 159
12.4 Conclusion, 159
References, 160

**13 Frameworks for Regulations, Standardization, and Authentication of Cardiovascular Herbal Drugs 164**

*Kumar CSP, Surya Prakasarao Kovvasu, and Gummadi RamaKrishna*

13.1 Introduction, 164
13.2 Regulatory Frameworks for Herbal Cardiovascular Drugs, 164
13.2.1 World Health Organization Guidelines, 164
13.2.2 United States Food and Drug Administration, 165
13.2.3 European Medicines Agency, 165
13.2.4 Indian Ministry of AYUSH, 165
13.3 Standardization Approaches for Herbal Cardiovascular Drugs, 166
13.3.1 Evaluation of Drugs Macroscopically and Microscopically, 166
13.3.2 Chromatographic Techniques, 166
13.3.3 Spectroscopic Methods, 167
13.3.4 Standardization by Using Markers, 167
13.4 Methods for Authentication, 167
13.4.1 Pharmacognostical Analysis, 167
13.4.2 Techniques in Molecular Analysis, 168
13.4.3 Chemometric and Metabolomic Profiling, 168
13.5 Case Studies, 168
13.5.1 *Terminalia arjuna*: A Cardioprotective Herb, 168
13.5.2 *Allium Sativum* (Garlic), 169
13.5.3 *Ginkgo biloba,* 169
13.6 Challenges and Opportunities, 170
13.7 Conclusion, 170
References, 170

**14 Transforming Drug Delivery Systems Through Artificial Intelligence and Machine Learning 172**

*Mohan Gandhi Bonthu, Veera R. Bitra, Alluri Pavani Gayatri, and Balakrishna Talamanchi*

14.1 Introduction, 172
14.1.1 Overview of Drug Delivery Systems, 172
14.1.2 Evolution from Conventional to Intelligent Drug Delivery, 172
14.1.3 Relevance of DDS in Cardiovascular and Phytomedicine Therapy, 172
14.1.4 The Need for Computational Transformation in DDS, 173

14.2 Fundamentals of Artificial Intelligence and Machine Learning in Pharmaceutical Sciences, 173
14.2.1 Evolution and Relevance of AI in Medicine and Pharmaceutics, 174
14.2.2 Major Subfields of AI and Their Pharmaceutical Relevance, 174
14.2.3 Categories of Machine Learning in Pharmaceutical Applications, 174
14.2.4 Integration of Big Data, Omics, and AI in Pharmaceutics, 175
14.3 AI and ML in Drug Discovery and Formulation Design, 175
14.3.1 AI in Drug Discovery and Lead Optimization, 175
14.3.2 ML-Based Prediction of Drug–Excipient Compatibility and Stability, 175
14.3.3 AI in Formulation Optimization, 175
14.3.4 Predictive Modeling for Solubility, Permeability, and Bioavailability, 177
14.3.5 Case Studies: AI in Formulation Development, 177
14.3.6 AI and ML in Process Control and Scale-Up, 177
14.3.7 AI in Regulatory and Quality by Design, 177
14.4 Role of AI and ML in Modern Drug Delivery Systems, 177
14.4.1 Advanced Drug Delivery Systems, 177
14.4.2 AI-Assisted Nanocarrier Design for Enhanced Targeting, 177
14.4.3 AI in Controlled and Sustained Drug Release Modeling, 178
14.4.4 AI in Stimuli-Responsive and Smart Delivery Systems, 178
14.4.5 Machine Learning for Pharmacokinetic and Pharmacodynamic Prediction, 178
14.4.6 Integration of AI with Emerging Technologies, 178
14.5 Transforming Phytomedicine Delivery Through Artificial Intelligence and Machine Learning, 178
14.5.1 Challenges in Conventional Phytomedicine Delivery, 178
14.5.2 AI in Herbal Nanocarriers and Advanced Delivery Systems, 179
14.5.3 Predictive Toxicity, ADME, and Safety Profiling for Herbal Actives, 179
14.5.4 Personalized Phytotherapy and AI-Enabled Precision Delivery, 180
14.5.5 AI-Guided Combination Therapy and Synergy Prediction, 180
14.6 AI and ML in Cardiovascular Drug Delivery, 180
14.6.1 AI in Prediction of Cardiovascular Diseases and Drug Targeting, 180
14.6.2 AI-Enhanced Nanocarrier Delivery for Cardiovascular Therapy, 180
14.6.3 Smart and Responsive Cardiovascular DDS Progressive Cardiovascular Disorders, 180
14.6.4 AI in Pharmacokinetic/Pharmacodynamic Modeling for Cardiovascular Drugs, 180
14.6.5 AI and Digital Biomarkers for Adaptive Drug Delivery, 181
14.6.6 Integration with Phytomedicine for Cardiovascular Health, 181
14.6.7 Federated Learning and Multicenter Cardiovascular Data Integration, 181
14.6.8 Case Study and Future Trends, 181
14.7 Clinical Development and Regulatory Applications of AI in Drug Delivery and Phytomedicine, 181
14.7.1 AI in Clinical Trial Design and Optimization, 181
14.7.2 Virtual Clinical Trials and *in silico* Modeling, 181
14.7.3 AI-Driven Pharmacovigilance and Post-marketing Surveillance, 182
14.7.4 AI in Regulatory Science and Quality Assurance, 182
14.7.5 Data Governance, Privacy, and Ethical Considerations, 182
14.7.6 Challenges and Limitations in AI-Based Clinical Implementation, 182
14.8 Ethical, Safety, and Implementation Challenges in AI-Based Drug Delivery Systems, 182
14.9 Future Perspectives and Opportunities, 183
14.10 Conclusion, 183
References, 184

15 Future Challenges and Opportunities in Herbal-Based Cardiovascular Therapy 188

*Gummadi Veda Priya, Saurabh Gupta, Karri Swathi Priya, and Arya Lakshmi Marisetti*

15.1 Introduction, 188
15.2 Self-Care Through Behavioral and Lifestyle Change, 188
15.2.1 Integrative Medicine Models, 189
15.2.2 Integrative Health, 189
15.2.3 Conventional Medicine, 189
15.2.4 Integrative Medicine, 189
15.2.5 Life Style Medicine, 189
15.3 Diet Impact on Cardiovascular Health, 189
15.4 Growing Global Interest in Natural Therapies, 190
15.4.1 Rich Source of Bioactive Compounds, 191
15.4.2 Advancements in Phytochemistry, 191
15.5 Key Challenges Facing Herbal-Based Therapies for Cardiovascular Diseases, 191
15.5.1 Inadequate Standardization and Quality Control, 191
15.5.2 Quality Control, 191
15.5.3 Need for the Standardization of Herbal Medicines, 192
15.5.4 Analytical Techniques for Quality Control and Standardization, 192
15.5.5 WHO Standardization Parameters and Pharmacognostical Quality Control Parameters for Herbal Drugs, 192
15.5.6 Scientific Validation and Clinical Trials, 193
15.6 Challenges Faced by Herbal Medical Practitioners, 193
15.7 Future Trends and Opportunities, 194
15.7.1 Wearable Devices, 195
15.7.2 3D Printing Technology, 195
15.7.3 Bioengineering and Regenerative Medicine, 195
15.7.4 Imaging Technologies and Digital Simulation, 195
15.7.5 Role of Genetic Profiling and Biomarkers, 195
15.8 Future Research Directions, 195
15.8.1 Genomic and Metabolomic Profiling of Medicinal Plants, 195
15.8.2 Personalized Herbal Medicine Using Pharmacogenomics, 196
15.8.3 Exploring Gut Microbiota Modulation via Herbal Interventions, 196
15.8.4 Green Chemistry for Eco-Friendly Extraction of Bioactives, 196
15.8.5 Sustainability and Eco-Consciousness, 196
15.9 Potential Benefits and Challenges, 197
15.10 Conclusion, 197
References, 197

**Index** 201